凋亡信号分子作为头颈部鳞状细胞癌治疗靶点
该研究在TCGA头颈癌数据集和Montefiore医学中心队列中检测BAK、BAX、BCL2L1和MCL1的mRNA表达,并在HNSCC细胞系中评估蛋白表达;发现这些促/抗凋亡分子表达均显著高于BCL2,联合ABT-263/A-1210477或硼替佐米可诱导接近或超过星形孢菌素对照的凋亡反应。
要点
- HNSCC中BCL2L1和MCL1等抗凋亡分子表达显著高于BCL2。
- 联合ABT-263与A-1210477或硼替佐米可有效诱导HNSCC细胞凋亡。
- 诱导凋亡是HNSCC潜在治疗策略,但需克服冗余抗凋亡信号。
核心结论
- HNSCC细胞依赖BCL-xL和MCL-1过表达抑制凋亡,诱导凋亡是潜在治疗选择,但策略需克服冗余抗凋亡信号。
研究设计与样本
- 研究检测TCGA头颈癌数据集和Montefiore医学中心队列中BAK、BAX、BCL2、BCL2L1和MCL1的mRNA表达,并在HN30、HN31、HN5、MDA686LN、UMSCC47细胞系中评估蛋白表达,用细胞活力和Annexin V实验评估ABT-263、A-1210477和硼替佐米的疗效与凋亡潜能。
主要发现
- 在TCGA和MMC数据集中,BAK、BAX、BCL2L1和MCL1表达均显著高于BCL2表达。
- HNSCC细胞系蛋白表达呈现相同模式。
- 联合ABT-263/A-1210477或硼替佐米治疗的凋亡反应接近或超过星形孢菌素对照。
临床怎么用
- 提示BCL-xL和MCL-1是HNSCC凋亡诱导治疗的潜在靶点,联合抑制冗余抗凋亡信号可能增强疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate BCL-2 family signaling molecules in head and neck squamous cell carcinoma (HNSCC) and examine the ability of therapeutic agents with variable mechanisms of action to induce apoptosis in HNSCC cells. METHODS: messenger ribonculeic acid (mRNA) expression of BAK, BAX, B-cell lymphoma (Bcl-2), BCL2 Like 1 (BCL2L1), and MCL1 were measured in The Cancer Genome Atlas (TCGA) head and neck cancer dataset, as well as in a dataset from a cohort at Montefiore Medical Center (MMC). Protein expression was similarly evaluated in a panel of HNSCC cell lines (HN30, HN31, HN5, MDA686LN, UMSCC47). Cell viability and Annexin V assays were used to assess the efficacy and apoptotic potential of a variety of agents (ABT-263 [navitoclax], A-1210477, and bortezomib. RESULTS: Expression of BAK, BAX, BCL2L1, and MCL1 were each significantly higher than expression of BCL2 in the TCGA and MMC datasets. Protein expression demonstrated the same pattern of expression when examined in HNSCC cell lines. Treatment with combined ABT-263 (navitoclax)/A-1210477 or with bortezomib demonstrated apoptosis responses that approached or exceeded treatment with staurospaurine control. CONCLUSION: HNSCC cells rely on inhibition of apoptosis via BCL-xL and MCL-1 overexpression, and induction of apoptosis remains a potential therapeutic option as long as strategies overcome redundant anti-apoptotic signals. LEVEL OF EVIDENCE: NA Laryngoscope, 130:2643-2649, 2020.
引用
- Ow TJ, Thomas C, Fulcher CD, et al. Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma. Laryngoscope. 2020. PMID: 31894587. doi:10.1002/lary.28441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。